{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:14:24Z","timestamp":1790014464339,"version":"4.0.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40264-025-01644-4","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T17:20:46Z","timestamp":1767806446000},"page":"581-590","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluating COVID-19 Vaccine Masking and Unmasking Methods in Two National Pharmacovigilance Databases"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9793-4356","authenticated-orcid":false,"given":"Oskar","family":"Rachwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2905-2475","authenticated-orcid":false,"given":"Mar","family":"Guti\u00e9rrez-Lob\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0436-0242","authenticated-orcid":false,"given":"Nuria Sols","family":"Cueto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4998-214X","authenticated-orcid":false,"given":"Araceli Nu\u00f1ez","family":"Ventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7992-8933","authenticated-orcid":false,"given":"Cristina","family":"Fern\u00e1ndez-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8965-3224","authenticated-orcid":false,"given":"Florence P. A. M.","family":"van Hunsel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9222-5965","authenticated-orcid":false,"given":"Joep H. G.","family":"Scholl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2993-6577","authenticated-orcid":false,"given":"Mar\u00eda","family":"Gordillo-Mara\u00f1\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2236-1398","authenticated-orcid":false,"given":"Eug\u00e8ne P.","family":"van Puijenbroek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"1644_CR1","unstructured":"The importance of pharmacovigilance: World Health Organisation; 2002. 1 Jan 2002."},{"issue":"2","key":"1644_CR2","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/cpt.879","volume":"103","author":"K Klein","year":"2018","unstructured":"Klein K, Scholl JHG, De Bruin ML, van Puijenbroek EP, Leufkens HGM, Stolk P. When more is less: an exploratory study of the precautionary reporting bias and its impact on safety signal detection. Clin Pharmacol Ther. 2018;103(2):296\u2013303.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"1644_CR3","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1007\/s11096-018-0711-z","volume":"40","author":"P Baldo","year":"2018","unstructured":"Baldo P, Francescon S, Fornasier G. Pharmacovigilance workflow in Europe and Italy and pharmacovigilance terminology. Int J Clin Pharm. 2018;40(4):748\u201353.","journal-title":"Int J Clin Pharm"},{"issue":"12","key":"1644_CR4","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s40264-014-0240-1","volume":"37","author":"AC Pacurariu","year":"2014","unstructured":"Pacurariu AC, Coloma PM, van Haren A, Genov G, Sturkenboom MC, Straus SM. A description of signals during the first 18 months of the EMA pharmacovigilance risk assessment committee. Drug Saf. 2014;37(12):1059\u201366.","journal-title":"Drug Saf"},{"issue":"1","key":"1644_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3\u201310.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"1644_CR6","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2165\/00002018-200225060-00010","volume":"25","author":"AC Egberts","year":"2002","unstructured":"Egberts AC, Meyboom RH, van Puijenbroek EP. Use of measures of disproportionality in pharmacovigilance: three Dutch examples. Drug Saf. 2002;25(6):453\u20138.","journal-title":"Drug Saf"},{"key":"1644_CR7","unstructured":"Gu\u00eda para la detecci\u00f3n de Se\u00f1ales del sistema Espa\u00f1ol de Farmacovigilancia de medicamentos de uso Humano (SEFV-H)."},{"issue":"6","key":"1644_CR8","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V, et al. The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): explanation and elaboration. Drug Saf. 2024;47(6):585\u201399.","journal-title":"Drug Saf"},{"issue":"379","key":"1644_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.o2588","volume":"3","author":"C Khouri","year":"2022","unstructured":"Khouri C, Fusaroli M, Salvo F, Raschi E. Transparency and robustness of safety signals. BMJ. 2022;3(379):o2588.","journal-title":"BMJ"},{"key":"1644_CR10","unstructured":"Screening for adverse reactions in Eudravigilance: European Medicines Agency; 2016. Report No.: EMA\/849944\/2016."},{"issue":"9","key":"1644_CR11","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1111\/jth.12622","volume":"12","author":"A Kant","year":"2014","unstructured":"Kant A, van Puijenbroek E, van Hunsel F. Reflections after the Diane affair. J Thromb Haemost. 2014;12(9):1385\u20137.","journal-title":"J Thromb Haemost"},{"issue":"5","key":"1644_CR12","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/j.1365-2125.2009.03400.x","volume":"67","author":"F van Hunsel","year":"2009","unstructured":"van Hunsel F, Passier A, van Grootheest K. Comparing patients\u2019 and healthcare professionals\u2019 ADR reports after media attention: the broadcast of a Dutch television programme about the benefits and risks of statins as an example. Br J Clin Pharmacol. 2009;67(5):558\u201364.","journal-title":"Br J Clin Pharmacol"},{"key":"1644_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-001607","author":"K Faasse","year":"2012","unstructured":"Faasse K, Gamble G, Cundy T, Petrie KJ. Impact of television coverage on the number and type of symptoms reported during a health scare: a retrospective pre-post observational study. BMJ Open. 2012. https:\/\/doi.org\/10.1136\/bmjopen-2012-001607.","journal-title":"BMJ Open"},{"issue":"11","key":"1644_CR14","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s40264-023-01346-9","volume":"46","author":"B Micallef","year":"2023","unstructured":"Micallef B, Dogn\u00e9 JM, Sultana J, Straus S, Nistic\u00f2 R, Serracino-Inglott A, et al. An exploratory study of the impact of COVID-19 vaccine spontaneous reporting on masking signal detection in EudraVigilance. Drug Saf. 2023;46(11):1089\u2013103.","journal-title":"Drug Saf"},{"issue":"6","key":"1644_CR15","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.therap.2024.03.002","volume":"79","author":"F Adja\u00ef","year":"2024","unstructured":"Adja\u00ef F, Fournier D, Dolladille C, Lebrun-Vignes B, Bihan K. Impact of the vaccination against SARS-CoV-2 campaign on disproportionality indicator from the WHO pharmacovigilance database: a competition bias study from case\/non-case analysis. Therapie. 2024;79(6):680\u201391.","journal-title":"Therapie"},{"issue":"1","key":"1644_CR16","doi-asserted-by":"publisher","first-page":"345","DOI":"10.21873\/invivo.13085","volume":"37","author":"K Yamaoka","year":"2023","unstructured":"Yamaoka K, Fujiwara M, Uchida M, Uesawa Y, Shimizu T. The influence of the rapid increase in the number of adverse event reports for COVID-19 vaccine on the disproportionality analysis using JADER. In Vivo. 2023;37(1):345\u201356.","journal-title":"In Vivo"},{"issue":"1","key":"1644_CR17","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40264-022-01253-5","volume":"46","author":"I Oosterhuis","year":"2023","unstructured":"Oosterhuis I, Scholl J, van Puijenbroek E, Kant A, van Hunsel F. Optimizing safety surveillance for COVID-19 vaccines at the National Pharmacovigilance Centre Lareb: one year of COVID-19 vaccine experience. Drug Saf. 2023;46(1):65\u201375.","journal-title":"Drug Saf"},{"key":"1644_CR18","unstructured":"SEFV-H Resumen de Actividad 2021: Agencia Espanola de Medicamentos y Productos Sanitarios; 2021."},{"issue":"10","key":"1644_CR19","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1002\/pds.3474","volume":"22","author":"K Juhlin","year":"2013","unstructured":"Juhlin K, Ye X, Star K, Nor\u00e9n GN. Outlier removal to uncover patterns in adverse drug reaction surveillance\u2014a simple unmasking strategy. Pharmacoepidemiol Drug Saf. 2013;22(10):1119\u201329.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"1644_CR20","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s40264-016-0413-1","volume":"39","author":"F Montastruc","year":"2016","unstructured":"Montastruc F, Salvo F, Arnaud M, B\u00e9gaud B, Pariente A. Signal of gastrointestinal congenital malformations with antipsychotics after minimising competition bias: a disproportionality analysis using data from Vigibase(\u00ae). Drug Saf. 2016;39(7):689\u201396.","journal-title":"Drug Saf"},{"issue":"3","key":"1644_CR21","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s40264-015-0375-8","volume":"39","author":"M Arnaud","year":"2016","unstructured":"Arnaud M, Salvo F, Ahmed I, Robinson P, Moore N, B\u00e9gaud B, et al. A method for the minimization of competition bias in signal detection from spontaneous reporting databases. Drug Saf. 2016;39(3):251\u201360.","journal-title":"Drug Saf"},{"issue":"2","key":"1644_CR22","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/pds.3530","volume":"23","author":"F Maignen","year":"2014","unstructured":"Maignen F, Hauben M, Hung E, Holle LV, Dogne JM. A conceptual approach to the masking effect of measures of disproportionality. Pharmacoepidemiol Drug Saf. 2014;23(2):208\u201317.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1644_CR23","unstructured":"Medical Dictionary for Regulatory Activities. 2024. Available from: meddra.org. Accessed 31 Oct 2024."},{"key":"1644_CR24","unstructured":"Eudravigilance System Overview. 2025. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/pharmacovigilance-research-development\/eudravigilance\/eudravigilance-system-overview. Accessed 11 July 2025."},{"key":"1644_CR25","unstructured":"Inclusion\/exclusion criteria for the \u201cImportant Medical Events\u201d list; 2021 18 March 2021."},{"key":"1644_CR26","unstructured":"ICH Topic E 2 A Clinical Safety Data Management: Definitions and Standards for Expedited Reporting. European Medicines Agency; 1995."},{"issue":"10","key":"1644_CR27","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1111\/bcp.15799","volume":"89","author":"JW Duijster","year":"2023","unstructured":"Duijster JW, Schoep ME, Nieboer TE, Jajou R, Kant A, van Hunsel F. Menstrual abnormalities after COVID-19 vaccination in the Netherlands: a description of spontaneous and longitudinal patient-reported data. Br J Clin Pharmacol. 2023;89(10):3126\u201338.","journal-title":"Br J Clin Pharmacol"},{"key":"1644_CR28","unstructured":"Larsson JGP. A case study in fitting area-proportional Euler diagrams with ellipses using eulerr. 2018. p. 84\u201391."},{"key":"1644_CR29","unstructured":"Vidlin S. Unmasking data in the COVID-19 vaccine era. Uppsala Reports 2022. https:\/\/uppsalareports.org\/articles\/unmasking-data-in-the-covid-19-vaccine-era\/. Accessed 19 Apr 2024."},{"key":"1644_CR30","unstructured":"2022 Annual Report on EudraVigilance for the European Parliament, the Council and the Commission; 2023. 20 Mar 2023."},{"issue":"6","key":"1644_CR31","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s40264-015-0289-5","volume":"38","author":"G Candore","year":"2015","unstructured":"Candore G, Juhlin K, Manlik K, Thakrar B, Quarcoo N, Seabroke S, et al. Comparison of statistical signal detection methods within and across spontaneous reporting databases. Drug Saf. 2015;38(6):577\u201387.","journal-title":"Drug Saf"},{"issue":"6","key":"1644_CR32","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40264-016-0405-1","volume":"39","author":"AF Wisniewski","year":"2016","unstructured":"Wisniewski AF, Bate A, Bousquet C, Brueckner A, Candore G, Juhlin K, et al. Good signal detection practices: evidence from IMI PROTECT. Drug Saf. 2016;39(6):469\u201390.","journal-title":"Drug Saf"},{"issue":"7","key":"1644_CR33","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s40264-022-01186-z","volume":"45","author":"R Harpaz","year":"2022","unstructured":"Harpaz R, DuMouchel W, Van Manen R, Nip A, Bright S, Szarfman A, et al. Signaling COVID-19 vaccine adverse events. Drug Saf. 2022;45(7):765\u201380.","journal-title":"Drug Saf"},{"issue":"6","key":"1644_CR34","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/clpt.2013.24","volume":"93","author":"R Harpaz","year":"2013","unstructured":"Harpaz R, DuMouchel W, LePendu P, Bauer-Mehren A, Ryan P, Shah NH. Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. Clin Pharmacol Ther. 2013;93(6):539\u201346.","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"1644_CR35","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1002\/pds.4623","volume":"27","author":"C Dodd","year":"2018","unstructured":"Dodd C, Pacurariu A, Osokogu OU, Weibel D, Ferrajolo C, Vo DH, et al. Masking by vaccines in pediatric drug safety signal detection in the EudraVigilance database. Pharmacoepidemiol Drug Saf. 2018;27(11):1249\u201356.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1644_CR36","first-page":"1","volume":"30","author":"H Matsuo","year":"2024","unstructured":"Matsuo H, Tanaka H, Endo K, Ishii T. Influence of rapidly increased numbers of reports on adverse events of the COVID-19 vaccine in the Japanese pharmacovigilance database on disproportionality analysis of antineoplastic drug-associated adverse cardiovascular events. Expert Opin Drug Saf. 2024;30:1\u20135.","journal-title":"Expert Opin Drug Saf"},{"key":"1644_CR37","unstructured":"Brighton Collaboration. List of advese events of special interest. https:\/\/brightoncollaboration.org\/tools\/aesi-lists\/. Accessed 7 May 2025."},{"key":"1644_CR38","unstructured":"Designated Medical Events 2025. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/post-authorisation\/pharmacovigilance-post-authorisation\/signal-management?utm_source=chatgpt.com#designated-medical-events-10341. Accessed 17 July 2025."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-025-01644-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-025-01644-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-025-01644-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T10:15:23Z","timestamp":1776334523000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-025-01644-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1644"],"URL":"https:\/\/doi.org\/10.1007\/s40264-025-01644-4","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"4 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Florence van Hunsel and Eug\u00e8ne van Puijenbroek are Editorial Board members of Drug Safety. These authors were not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. The other authors report no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The data that support the findings of this study are not publicly available. Access to the data is restricted based on the conditions for access within the Netherlands Pharmacovigilance centre Lareb and FEDRA data access policy described in\n                      \n                      . Subject to these conditions, data is available from the authors on reasonable request. Code used in the extraction and analysis of data is available upon reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code and data sharing"}},{"value":"Ethics approval was not needed for this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Study conception and design: OR, MGL, NSC, ANV, CFF, MGM, EvP and FHL. Data extraction and statistical analysis Lareb data: OR, JS and EvP. Data extraction and statistical analysis Spanish National Database: MGL. Interpretation of results and preparation draft manuscript: all authors. All authors reviewed the results and approved the definitive version of this manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}